Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7 - PubMed (original) (raw)
Comparative Study
Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7
C Issaad et al. Leukemia. 2000 Apr.
Abstract
There is currently no satisfactory model allowing analysis of dose-effect relationships of BCR-ABL proteins in human hematopoietic cells. To study comparatively the proliferative, differentiative and anti-apoptotic actions of different levels of BCR-ABL proteins in the context of the same cellular background, we have introduced the BCR-ABL gene into the GM-CSF-dependent pluripotent human cell line UT-7. Individual clones expressing BCR-ABL were analyzed by Western blots. After normalization to equivalent levels of endogenous ABL protein, 14 clones always grown in GM-CSF were found to express low but variable levels of BCR-ABL whereas two clones selected in the absence of GM-CSF expressed very high levels of BCR-ABL. All low-level BCR-ABL expressing clones exhibited a behavior similar to that of the GM-CSF-dependent parental cells as they ceased to proliferate upon growth factor deprivation and showed a strong proliferative response upon GM-CSF addition. One out of 14 clones showed progressive GM-CSF independence during culture over several weeks and was found to have a significant increase of BCR-ABL expression at that time. The resistance of this clone (E8-2) to different apoptotic stimuli was found to be increased as compared to its low BCR-ABL-expressing counterpart (E8-1) and similar to that observed in clones with very high levels of BCR-ABL (UT-7/9 and UT-7/11) which were totally resistant to apoptotic stimuli. When injected into nude mice, parental UT-7 cells and clones with low-level of BCR-ABL were not tumorigenic over 10 weeks of observation whereas UT-7 clones with high levels of BCR-ABL (UT-7/9, UT-7/11 and UT-7/E8-2) induced aggressive tumors in 2-4 weeks with a significant correlation between the amount of BCR-ABL protein and the rate of tumor growth. In conclusion, the establishment of an in vitro and in vivo CML model using UT-7 cells suggests for the first time in human cells, that the fully transformed phenotype induced by BCR-ABL requires high levels of BCR-ABL expression. These findings suggest that variable levels of BCR-ABL in primary patient cells could also be responsible for the different phenotypic features seen in chronic and acute phases of CML, such as the differentiation ability induced by growth factors.
Similar articles
- Primitive interleukin 3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo.
Jiang X, Ng E, Yip C, Eisterer W, Chalandon Y, Stuible M, Eaves A, Eaves CJ. Jiang X, et al. Blood. 2002 Nov 15;100(10):3731-40. doi: 10.1182/blood-2002-05-1324. Epub 2002 Jul 5. Blood. 2002. PMID: 12393460 - Stem cell factor and chronic myeloid leukemia CD34+ cells.
Moore S, McDiarmid LA, Hughes TP. Moore S, et al. Leuk Lymphoma. 2000 Jul;38(3-4):211-20. doi: 10.3109/10428190009087013. Leuk Lymphoma. 2000. PMID: 10830729 Review. - Disease progression in a murine model of bcr/abl leukemogenesis.
van Etten RA. van Etten RA. Leuk Lymphoma. 1993;11 Suppl 1:239-42. doi: 10.3109/10428199309047893. Leuk Lymphoma. 1993. PMID: 8251903 Review.
Cited by
- Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells.
Modi H, McDonald T, Chu S, Yee JK, Forman SJ, Bhatia R. Modi H, et al. Blood. 2007 Jun 15;109(12):5411-21. doi: 10.1182/blood-2006-06-032490. Epub 2007 Mar 8. Blood. 2007. PMID: 17347407 Free PMC article. - RAPSYN-mediated neddylation of BCR-ABL alternatively determines the fate of Philadelphia chromosome-positive leukemia.
Zhao M, Dai B, Li X, Zhang Y, Qiao C, Qin Y, Li Z, Li Q, Wang S, Yang Y, Chen Y. Zhao M, et al. Elife. 2024 Jun 12;12:RP88375. doi: 10.7554/eLife.88375. Elife. 2024. PMID: 38865175 Free PMC article. - Modeling the influence of stromal microenvironment in the selection of ENU-induced BCR-ABL1 mutants by tyrosine kinase inhibitors.
Aggoune D, Tosca L, Sorel N, Bonnet ML, Dkhissi F, Tachdjian G, Bennaceur-Griscelli A, Chomel JC, Turhan AG. Aggoune D, et al. Oncoscience. 2014 Jan 30;1(1):57-68. doi: 10.18632/oncoscience.9. eCollection 2014. Oncoscience. 2014. PMID: 25593988 Free PMC article. - Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML).
Gentil M, Hugues P, Desterke C, Telliam G, Sloma I, Souza LEB, Baykal S, Artus J, Griscelli F, Guerci A, Johnson-Ansah H, Foudi A, Bennaceur-Griscelli A, Turhan AG. Gentil M, et al. PLoS One. 2018 Aug 9;13(8):e0200923. doi: 10.1371/journal.pone.0200923. eCollection 2018. PLoS One. 2018. PMID: 30091999 Free PMC article. - Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias.
Jaiswal S, Traver D, Miyamoto T, Akashi K, Lagasse E, Weissman IL. Jaiswal S, et al. Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):10002-7. doi: 10.1073/pnas.1633833100. Epub 2003 Jul 30. Proc Natl Acad Sci U S A. 2003. PMID: 12890867 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous